Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline
Portfolio Pulse from Vandana Singh
Vertex Pharmaceuticals Inc's Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 billion, driven by the strong uptake of Trikafta/Kaftrio. The company's gene-editing therapy for sickle cell disease, in collaboration with CRISPR Therapeutics AG, is under FDA review. Vertex raised its full-year sales forecast for its cystic fibrosis treatments. Analysts remain positive on Vertex's programs in Type 1 diabetes and pain.
August 04, 2023 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics AG's gene-editing therapy for sickle cell disease, in collaboration with Vertex Pharmaceuticals, is under FDA review.
The FDA review of the gene-editing therapy for sickle cell disease could potentially have a positive impact on CRISPR Therapeutics. The collaboration with Vertex Pharmaceuticals also adds to the company's credibility.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Vertex Pharmaceuticals reported strong Q2 sales and raised its full-year forecast. Analysts remain positive on the company's programs.
The strong Q2 sales and raised forecast indicate a positive outlook for Vertex Pharmaceuticals. The company's programs in Type 1 diabetes and pain are also seen positively by analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100